-
1.发明申请公开(公告)号：US20170240636A1
公开(公告)日：2017-08-24
申请号：US15515461
申请日：2015-09-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xavier Valencia , John P. Throup , Steven G. Nadler , Suzamme J. Suchard , Dominique Duchesne , Xiaoni Liu , Rong Shi , Diane E. Shevell , Jenny H. Xie , Marek Honczarenko
IPC: C07K16/28 , A61K45/06 , A61K39/395
CPC classification number: C07K16/2818 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/565 , C07K2317/569 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/31
Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
-
公开(公告)号：US11708405B2
公开(公告)日：2023-07-25
申请号：US16728757
申请日：2019-12-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Mohan Srinivasan , Shrikant Deshpande , Qihong Zhao , Huadong Sun , Ginger Rakestraw , Guodong Chen , Richard Y. Huang , Steven Sheriff , Cristian Rodriguez , John P. Throup , Rose A. Dibella
CPC classification number: C07K16/24 , A61K9/0019 , A61K47/6845 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
-
Patent Agency Ranking
3.发明申请公开(公告)号：US20200247890A1
公开(公告)日：2020-08-06
申请号：US16842885
申请日：2020-04-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xavier Valencia , John P. Throup , Steven G. Nadler , Suzanne J. Suchard , Dominique Duchesne , Xiaoni Liu , Rong Shi , Diane E. Shevell , Jenny H. Xie , Marek Honczarenko
IPC: C07K16/28 , A61K47/60 , A61K39/395 , A61K45/06
Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
-
公开(公告)号：US10556948B2
公开(公告)日：2020-02-11
申请号：US15364612
申请日：2016-11-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Mohan Srinivasan , Shrikant Deshpande , Qihong Zhao , Huadong Sun , Ginger Rakestraw , Guodong Chen , Richard Y. Huang , Steven Sheriff , Cristian Rodriguez , John P. Throup , Rose A. Dibella
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
-
5.发明授权公开(公告)号：US11912769B2
公开(公告)日：2024-02-27
申请号：US17584207
申请日：2022-01-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xavier Valencia , John P. Throup , Steven G. Nadler , Suzanne J. Suchard , Dominique Duchesne , Xiaoni Liu , Rong Shi , Diane E. Shevell , Jenny H. Xie , Marek Honczarenko
IPC: A61K39/395 , C07K16/28 , A61K47/60 , A61K45/06 , A61K39/00
CPC classification number: C07K16/2818 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/565 , C07K2317/569 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/31
Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
-
6.发明申请公开(公告)号：US20220144951A1
公开(公告)日：2022-05-12
申请号：US17584207
申请日：2022-01-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xavier Valencia , John P. Throup , Steven G. Nadler , Suzanne J. Suchard , Dominique Duchesne , Xiaoni Liu , Rong Shi , Diane E. Shevell , Jenny H. Xie , Marek Honczarenko
IPC: C07K16/28 , A61K47/60 , A61K39/395 , A61K45/06
Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
-
7.发明授权公开(公告)号：US11267888B2
公开(公告)日：2022-03-08
申请号：US16842885
申请日：2020-04-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xavier Valencia , John P. Throup , Steven G. Nadler , Suzanne J. Suchard , Dominique Duchesne , Xiaoni Liu , Rong Shi , Diane E. Shevell , Jenny H. Xie , Marek Honczarenko
IPC: A61K39/395 , C07K16/28 , A61K47/60 , A61K45/06 , A61K39/00
Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
-
-
-
-
-
-
Search Results
7
records
(took 0.015 seconds)
